Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1031 (LINC01031) is a long intergenic non-coding RNA (lincRNA) that does not overlap protein-coding genes and is greater than 200 nucleotides in length[1][5][7]. LINC01031 is expressed in various tissues and has been identified as a risk-associated lincRNA in lung squamous cell carcinoma, where its overexpression correlates with poor clinical prognosis and may mark malignancy[2]. While the specific mechanisms of LINC01031 function remain to be elucidated, lincRNAs such as LINC01031 are thought to regulate gene expression, chromatin remodeling, and RNA stability, and could modulate the expression of neighboring genes in a tissue-specific manner[1][5]. The precise physiological and pathological roles of LINC01031 are under investigation, but current evidence supports its relevance as a molecular marker and a potential therapeutic target in oncology[2].
Not determined for drugs, as no drugs are known to act directly on LINC01031[2]. Potential molecular functions (not drug mechanisms) include transcriptional and chromatin landscape regulation, as established for lincRNAs generally[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1031 (LINC01031).